protein

Interleukin 1 Receptor Antagonist, Recombinant, Human (IL-1RA, IL1RA, IL-1ra3, IL-1RN, IL1RN, Anakinra, DIRA, ICIL-1RA, IL1 Inhibitor, IL1F3, IRAP, MGC10430, MVCD4)

MBS650714

0.02 mg

550 USD

Recombinant Protein

Interleukin 1 Receptor Antagonist, Recombinant, Human (IL-1RA, IL1RA, IL-1ra3, IL-1RN, IL1RN, Anakinra, DIRA, ICIL-1RA, IL1 Inhibitor, IL1F3, IRAP, MGC10430, MVCD4)

Interleukin 1 Receptor Antagonist

interleukin 1 receptor antagonist; Interleukin-1 receptor antagonist protein; interleukin-1 receptor antagonist protein; IL1 inhibitor; IL1RN (IL1F3); OTTHUMP00000162022; OTTHUMP00000162023; OTTHUMP00000162024; OTTHUMP00000203731; type II interleukin-1 receptor antagonist; intracellular IL-1 receptor antagonist type II; intracellular interleukin-1 receptor antagonist (icIL-1ra); interleukin 1 receptor antagonist; ICIL-1RA; IL1 inhibitor

IL1RN; IL1RN; DIRA; IRAP; IL1F3; IL1RA; MVCD4; IL-1RN; IL-1ra; IL-1ra3; ICIL-1RA; MGC10430; IL1F3; IL1RA

IL1RA_HUMAN

Highly Purified. ~98% (SDS PAGE).

Supplied as a lyophilized powder from TBS. Reconstitute with 200ul sterile dH2O.

Lyophilized powder may be stored at -20 degree C. Stable for 12 months at -20 degree C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Reconstituted product is stable for 6 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Suitable for use in Functional Assays. Dilution: Functional Assays: 20-40ng/ml

Biological Activity: In an assay of dose dependent inhibition of IL-1 stimulation of D10S cells, the ED50 was expectedto be 20-40ng/ml. Endotoxin Level: 0.1ng/ug

Growth Factors, Cytokines; Growth Factors-Interleukin

Interleukin-1 receptor antagonist (IL-1RA) is a naturally occurring protein which inhibits the activity of IL-1 alpha and IL-1 beta by competitively blocking binding to cell surface receptors for IL-1.

186386

P18510

~17kD/153aa

Cytokine Signaling In Immune System Pathway (366171); IL-1 Signaling Pathway (198908); IL1-mediated Signaling Events Pathway (137944); Immune System Pathway (106386); Interleukin-1 Signaling Pathway (160141); Signaling By Interleukins Pathway (160140)

The protein encoded by this gene is a member of the interleukin 1 cytokine family. This protein inhibits the activities of interleukin 1, alpha (IL1A) and interleukin 1, beta (IL1B), and modulates a variety of interleukin 1 related immune and inflammatory responses. This gene and five other closely related cytokine genes form a gene cluster spanning approximately 400 kb on chromosome 2. A polymorphism of this gene is reported to be associated with increased risk of osteoporotic fractures and gastric cancer. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq]

Function: Inhibits the activity of IL-1 by binding to its receptor. Has no IL-1 like activity. Subcellular location: Isoform 1: Secreted. Isoform 2: Cytoplasm. Isoform 3: Cytoplasm. Isoform 4: Cytoplasm. Tissue specificity: The intracellular form of IL1RN is predominantly expressed in epithelial cells. Involvement in disease: Genetic variation in IL1RN is associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4) [. MIM:612628]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.Defects in IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) [. MIM:612852]; also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T-cells. DIRA is a rare, autosomal recessive, genetic autoinflammatory disease that results in sterile multifocal osteomyelitis (bone inflammation in multiple places), periostitis (inflammation of the membrane surrounding the bones), and pustulosis (due to skin inflammation) from birth. Ref.18. Pharmaceutical use: Available under the name Kineret (Amgen). Used for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis.

0.02 mg

550 USD